Study: Roflumilast cream 0.05% is safe, effective in young children with eczema
Once-daily roflumilast cream 0.05% is safe and effective for atopic dermatitis (AD) in patients ages 2 to 5 years, according ...
Maintenance of low eczema activity seen after about 80 days off tapinarof
Patients with atopic dermatitis (AD) who achieve completely clear skin with tapinarof (Vtama) cream maintain low disease ...
The American Journal of Managed Care8d
Ruxolitinib Cream Shows Long-Term Safety in AD, Potential for PN Treatment
Two posters presented at the 2025 American Academy of Dermatology Annual Meeting reaffirmed the impact of ruxolitinib cream ...
The American Journal of Managed Care3d
Atopic Dermatitis Treatment Strategies Using Ruxolitinib, Considering Crucial Role of Skin Microbiome
Lawrence F. Eichenfield, MD, FAAD, from Rady Children's Hospital and UC San Diego School of Medicine, highlighted the effectiveness of ruxolitinib cream as a nonsteroidal topical treatment for atopic ...
Healio8d
Adults, children maintain mild AD during treatment-free period follow Vtama cream 1%
Atopic dermatitis disease activity remained mild after patients treated with Vtama cream 1% achieved nearly 80 consecutive ...
Arcutis to Highlight Data from Phase 3 Trials for Scalp and Body Psoriasis and Atopic Dermatitis at the 83rd American Academy of Dermatology Meeting
Data demonstrated favorable safety and local tolerability of ZORYVE® (roflumilast) cream 0.15% in adults and children with atopic dermatitis (AD) ...
Managed Healthcare Executive8d
Drug Holidays Possible with Vtama in Atopic Dermatitis
A break from treatment with Vtama won’t lead to worsening of patients’ atopic dermatitis, finds a new analysis of an ...
Managed Healthcare Executive6d
Study Finds Opzelura Used As-Needed Improves Quality of Life | AAD 2025
The reduction in itch was the greatest contributor to quality-of-life improvement for adolescents and adults with atopic ...
Nasdaq9d
Arcutis Biotherapeutics Presents Positive Data on ZORYVE® Cream and Foam for Atopic Dermatitis and Psoriasis at 2025 AAD Annual Meeting
Approximately 35 million individuals in the U.S. suffer from atopic dermatitis and psoriasis, highlighting a substantial market opportunity for ZORYVE products. Recognition of ZORYVE cream for ...
HealthDay2d
Roflumilast Cream 0.05 Percent Safe, Effective in Young Children With Eczema
Once-daily roflumilast cream 0.05 percent is safe and effective for atopic dermatitis (AD) in patients ages 2 to 5 ye ...